Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 803.60M | 806.60M | 829.00M | 824.50M | 825.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 803.60M | 806.60M | 829.00M | 824.50M | 825.30M |
| Cost of Revenue | 254.50M | 251.40M | 249.00M | 247.90M | 244.60M |
| Gross Profit | 549.10M | 555.20M | 580.00M | 576.60M | 580.70M |
| SG&A Expenses | 552.10M | 539.90M | 537.70M | 537.60M | 549.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 910.70M | 897.10M | 893.10M | 892.30M | 907.40M |
| Operating Income | -107.10M | -90.50M | -64.10M | -67.80M | -82.10M |
| Income Before Tax | -129.20M | -111.80M | -399.80M | -395.10M | -425.30M |
| Income Tax Expenses | -100.00K | 800.00K | 100.00K | -29.20M | -24.80M |
| Earnings from Continuing Operations | -129.10 | -112.60 | -399.90 | -365.90 | -400.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -129.10M | -112.60M | -399.90M | -365.90M | -400.50M |
| EBIT | -107.10M | -90.50M | -64.10M | -67.80M | -82.10M |
| EBITDA | -56.90M | -40.30M | -12.30M | -14.10M | -26.20M |
| EPS Basic | -1.36 | -1.20 | -4.32 | -3.95 | -4.33 |
| Normalized Basic EPS | -0.80 | -0.69 | -0.50 | -0.51 | -0.59 |
| EPS Diluted | -1.37 | -1.20 | -4.32 | -3.95 | -4.34 |
| Normalized Diluted EPS | -0.80 | -0.69 | -0.50 | -0.51 | -0.59 |
| Average Basic Shares Outstanding | 377.50M | 374.90M | 372.60M | 370.30M | 368.10M |
| Average Diluted Shares Outstanding | 377.50M | 374.90M | 372.60M | 370.30M | 368.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |